Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsPeripheral Blood Stem Cell TransplantationMultiple MyelomaMelphalanTransplantation, HomologousBone MarrowBone Marrow TransplantationTransplantation ConditioningTreatment OutcomeCyclophosphamideBone Marrow CellsRemission InductionDisease-Free SurvivalSalvage TherapyEtoposideStem CellsHodgkin DiseaseLymphoma, Non-HodgkinSurvival RateHematopoietic Stem Cell MobilizationVincristineCytarabineRecurrenceSurvival AnalysisBone Marrow PurgingCarmustineMyeloablative AgonistsGraft vs Host DiseaseDoxorubicinHematopoietic Stem CellsThiotepaWhole-Body IrradiationPrognosisHematologic NeoplasmsAntineoplastic AgentsRetrospective StudiesChemotherapy, AdjuvantBusulfanLymphoma, Mantle-CellFollow-Up StudiesAntibodies, Monoclonal, Murine-DerivedAmyloidosisGranulocyte Colony-Stimulating FactorGraft SurvivalDexamethasoneBone and BonesAntigens, CD34Boronic AcidsAntineoplastic Agents, AlkylatingTime FactorsPyrazinesCisplatinPrednisoneLymphoma, FollicularIfosfamideAutograftsInduction ChemotherapyLymphoma, T-Cell, PeripheralLymphomaThalidomideMesenchymal Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseLiver TransplantationLeukemia, Myeloid, AcuteTransplantation ChimeraLeukapheresisNeoplasm, ResidualCarboplatinPodophyllotoxinAntibodies, MonoclonalTissue DonorsMaintenance ChemotherapyNeoplasm Recurrence, LocalMyelodysplastic SyndromesProspective StudiesDrug Administration ScheduleHematopoiesisNeoplasm StagingCell TransplantationCell DifferentiationBreast NeoplasmsCord Blood Stem Cell TransplantationMitoxantroneLymphoma, B-CellBone Marrow DiseasesLeukemiaIdarubicinLeukemia, MyeloidNeoplasms, Second PrimaryBleomycinKidney TransplantationBlood Transfusion, AutologousMethotrexateImmunosuppressive AgentsHistocompatibility TestingEmbryonic Stem Cells